Neurogene Entered Securities Purchase Agreement For A PIPE Investment, Expected To Result In Gross Proceeds Of $200M
Neurogene Entered Securities Purchase Agreement For A PIPE Investment, Expected To Result In Gross Proceeds Of $200M
Pursuant to the terms of the securities purchase agreement, Neurogene is selling an aggregate of (i) 1,835,000 shares of its common stock ("Common Stock") at a purchase price of $50.00 per share and (ii) pre-funded warrants to purchase 2,165,042 shares of Common Stock at a price of $49.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share. Following the transaction, there will be approximately 21.0 million shares of common stock outstanding (assuming the exercise in full of all pre-funded warrants). The PIPE financing is expected to close on or about November 5, 2024, subject to satisfaction of customary closing conditions.
根據證券購買協議條款，紐羅吉將以每股50.00美元的價格出售（i）183.5萬股普通股（" Common Stock "）和（ii）預融資認股權證，以每張49.999美元的價格購買216.5042萬股普通股。預融資認股權證的行使價格爲每股0.001美元。交易完成後，假設所有預融資認股權證全部行使，普通股總股數約爲2100萬股。PIPE融資預計將於2024年11月5日左右結束，視具有慣常的結束條件而定。
